HUP0204023A2 - Pirrolidinacetamidszármazék alkalmazása önmagában vagy kombinációban központi idegrendszeri zavarok kezelésére és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Pirrolidinacetamidszármazék alkalmazása önmagában vagy kombinációban központi idegrendszeri zavarok kezelésére és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0204023A2
HUP0204023A2 HU0204023A HUP0204023A HUP0204023A2 HU P0204023 A2 HUP0204023 A2 HU P0204023A2 HU 0204023 A HU0204023 A HU 0204023A HU P0204023 A HUP0204023 A HU P0204023A HU P0204023 A2 HUP0204023 A2 HU P0204023A2
Authority
HU
Hungary
Prior art keywords
treatment
combination
pharmaceutical compositions
compositions containing
cns disorders
Prior art date
Application number
HU0204023A
Other languages
English (en)
Inventor
Henrik Klitgaard
Yves Lamberty
Alain Matagne
Tony Waegemans
Original Assignee
Ucb, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb, S.A. filed Critical Ucb, S.A.
Publication of HUP0204023A2 publication Critical patent/HUP0204023A2/hu
Publication of HUP0204023A3 publication Critical patent/HUP0204023A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

A találmány tárgya (I) képletű levetiracetam alkalmazása bipoláriszavarok, mánia, migrén és krónikus és neuropathiás fájdalom kezeléséreszolgáló gyógyszer előállítására. A találmány tárgyát képezi továbbágyógyászati készítmény bipoláris zavarok, mánia, migrén és krónikus ésneuropathiás fájdalom kezelésére, amely levetiracetam terápiásanhatékony mennyiségét és egy gyógyászatilag alkalmazható vivőanyagottartalmaz, illetve levetiracetam tartalmú gyógyászati készítményalkalmazása olyan páciens kezelésére szolgáló gyógyszer előállítására,akinek legalább egy GABAA receptorok mediálta neurális gátlástindukáló vegyületet adagolnak olyan mennyiségben, ami önmagában advanem lenne terápiásan hatékony. Ó
HU0204023A 1999-12-01 2000-11-27 A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders and pharmaceutical compositions containing them HUP0204023A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99123803 1999-12-01
EP99124269 1999-12-01
PCT/EP2000/011808 WO2001039779A1 (en) 1999-12-01 2000-11-27 A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders

Publications (2)

Publication Number Publication Date
HUP0204023A2 true HUP0204023A2 (hu) 2003-03-28
HUP0204023A3 HUP0204023A3 (en) 2005-03-29

Family

ID=26153183

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0204023A HUP0204023A3 (en) 1999-12-01 2000-11-27 A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders and pharmaceutical compositions containing them

Country Status (32)

Country Link
US (2) US6903130B1 (hu)
EP (4) EP1600169A3 (hu)
JP (2) JP4249415B2 (hu)
KR (1) KR20030016205A (hu)
CN (1) CN100525761C (hu)
AR (1) AR026610A1 (hu)
AT (1) ATE361751T1 (hu)
AU (1) AU773418B2 (hu)
BG (1) BG106708A (hu)
BR (1) BR0015974A (hu)
CA (2) CA2475026A1 (hu)
CO (1) CO5261590A1 (hu)
CZ (1) CZ20021904A3 (hu)
DE (1) DE60034815T2 (hu)
EE (1) EE200200274A (hu)
ES (1) ES2287039T3 (hu)
HK (1) HK1052647B (hu)
HU (1) HUP0204023A3 (hu)
IL (2) IL149530A0 (hu)
IS (1) IS6377A (hu)
MX (1) MXPA02005275A (hu)
MY (1) MY127980A (hu)
NO (1) NO20022585L (hu)
NZ (1) NZ518901A (hu)
PL (1) PL357472A1 (hu)
RO (1) RO121085B1 (hu)
RU (1) RU2261093C2 (hu)
SA (1) SA01210655B1 (hu)
SK (1) SK7492002A3 (hu)
TW (1) TWI238062B (hu)
WO (1) WO2001039779A1 (hu)
YU (1) YU37602A (hu)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US7683071B2 (en) 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
CA2433039C (en) 2000-12-28 2010-06-08 Daiichi Pharmaceutical Co., Ltd. Agent for therapeutic and prophylactic treatment of neuropathic pain
CA2438930A1 (en) * 2001-02-23 2002-09-06 Johns Hopkins University Treatment of tics, tremors and related disorders
AU2002344820B2 (en) * 2001-06-20 2006-12-14 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
CA2461961A1 (en) * 2001-10-08 2003-04-17 Ucb, S.A. Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
AU2003242538A1 (en) * 2002-05-14 2003-11-11 Ucb, S.A. Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
US20070135514A1 (en) * 2002-12-03 2007-06-14 Berkley Lynch Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
CA2505335C (en) 2002-12-11 2013-09-10 Daniel Aaron Moros Method of treating movement disorders using barbituric acid derivatives
WO2004083180A1 (en) * 2003-03-18 2004-09-30 Hetero Drugs Limited Novel crystalline forms of levetiracetam
GB0307860D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
WO2004093910A1 (ja) * 2003-04-22 2004-11-04 Astellas Pharma Inc. ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤
JP4715514B2 (ja) * 2003-10-03 2011-07-06 小野薬品工業株式会社 神経再生促進剤
EP1871363A4 (en) * 2005-03-30 2009-01-21 Genpharm Inc COMBINED STAGE PROCESS FOR PHARMACEUTICAL COMPOSITIONS
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2006127300A1 (en) * 2005-05-24 2006-11-30 Cambrex Charles City, Inc. SYNTHESIS OF (S)-α-ETHYL-2-OXO-1-PYRROLIDINEACETAMIDE
CN101068534B (zh) 2005-07-26 2011-09-07 Ucb医药有限公司 包括左乙拉西坦的药物组合物及其制备方法
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
FR2890563B1 (fr) * 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un agent thymoregulateur et les compositions pharmaceutiques qui la contiennent
CA2637925A1 (en) * 2006-01-24 2007-08-02 Teva Pharmaceutical Industries Ltd. Levetiracetam formulations and methods for their manufacture
WO2007144195A2 (en) * 2006-06-15 2007-12-21 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
CN101511388B (zh) * 2006-07-17 2012-10-24 特拉维夫大学拉莫特有限公司 含有精神药物或gaba激动剂和有机酸的缀合物以及它们在治疗疼痛和其它cns疾病中的用途
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
AU2007346591A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
ITMI20070770A1 (it) * 2007-04-16 2008-10-17 Brane Discovery S R L Impiego di dimiracetam nel trattamento del dolore cronico
AU2012201853B2 (en) * 2007-04-16 2013-06-27 Neurotune Ag Use of dimiracetam in the treatment of chronic pain
US8207369B2 (en) 2008-02-11 2012-06-26 Ramot At Tel-Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
CN102170874A (zh) 2008-08-06 2011-08-31 高思福斯中心（控股）有限公司 治疗精神病学障碍的组合物和方法
AU2009303834B2 (en) 2008-10-16 2016-08-11 The Johns Hopkins University Methods and compositions for improving cognitive function
PL389364A1 (pl) * 2009-10-23 2011-04-26 Uniwersytet Jagielloński Nowe zastosowanie pochodnych 2-pirolidonu
WO2011104637A2 (en) 2010-02-24 2011-09-01 Ramot At Tel-Aviv University Ltd. Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same
US8822539B2 (en) * 2010-03-28 2014-09-02 Children's Medical Center Corporation Combination therapies: inhibitors of GABA transaminase and NKCC1
WO2012038963A1 (en) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
AU2018208662B2 (en) * 2012-11-14 2020-07-23 The Johns Hopkins University Methods and Compositions for Treating Schizophrenia
JP6440625B2 (ja) * 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
KR101690175B1 (ko) * 2013-07-02 2016-12-27 경희대학교 산학협력단 고본 추출물을 유효성분으로 포함하는 불면증의 예방 또는 치료용 약학적 조성물
RU2538724C1 (ru) * 2013-12-19 2015-01-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Способ лечения эпилепсии
NZ722385A (en) 2014-01-21 2019-11-29 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
UA127921C2 (uk) * 2014-01-21 2024-02-14 Янссен Фармацевтика Нв Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування
RU2563124C1 (ru) * 2014-04-28 2015-09-20 Федеральное государственное бюджетное учреждение "Федеральный медицинский исследовательский центр психиатрии и наркологии имени В.П. Сербского" Министерства здравоохранения Российской Федерации (ФГБУ "ФМИЦПН им. В.П. Сербского" Минздрава России) Способ диагностики шизофрении
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam
AU2017341927B2 (en) * 2016-10-14 2021-12-16 CNS Biosciences, Inc. Treating neuropathic pain in spinal cord injured individuals
PL244071B1 (pl) * 2019-01-07 2023-11-27 Univ Jagiellonski Pochodne (2,5-dioksopirolidyn-1-ylo)(fenylo)-acetamidu i ich zastosowanie do leczenia chorób o podłożu neurologicznym

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412357D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8827389D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
EP0408782A1 (en) 1989-07-18 1991-01-23 Nauchnoissledovatelski Chimikopharmatzevtichen Institut Antihypoxic agent
GB9319732D0 (en) 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
HUP0004439A3 (en) 1997-12-16 2001-12-28 Warner Lambert Co 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
AU2463099A (en) 1998-01-23 1999-08-09 Warner-Lambert Company Gabapentin and its derivatives for the treatment of muscular and skeletal pain
DE19820381B4 (de) * 1998-05-07 2007-01-25 Trw Fahrwerksysteme Gmbh & Co Kg Verfahren zur Beeinflussung der Ventilkennlinie
US6495601B1 (en) 1998-12-23 2002-12-17 Cytoscan Sciences Llc Methods and compositions for treating conditions of the central and peripheral nervous systems using non-synaptic mechanisms
EP1141251A4 (en) * 1998-12-23 2004-09-22 Cytoscan Sciences Llc COMPOSITIONS, SCREENING TECHNIQUES AND METHODS FOR TREATING DISORDERS OF THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS
SK286104B6 (sk) * 1999-07-01 2008-03-05 Pharmacia & Upjohn Company Použitie (S,S) reboxetínu na prípravu lieku na liečenie alebo prevenciu chronickej bolesti
AU2003225813A1 (en) * 2002-03-18 2003-10-08 Roger K. Cady Preemptive prophylaxis of migraine
US20040116506A1 (en) * 2002-06-20 2004-06-17 Krusz John Claude Use of levetiracetam for treating or preventing acute headaches
US20070135514A1 (en) * 2002-12-03 2007-06-14 Berkley Lynch Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases

Also Published As

Publication number Publication date
NO20022585D0 (no) 2002-05-31
NZ518901A (en) 2004-08-27
MXPA02005275A (es) 2003-02-17
US20050187205A1 (en) 2005-08-25
DE60034815D1 (de) 2007-06-21
IS6377A (is) 2002-05-10
CA2392879C (en) 2005-03-29
KR20030016205A (ko) 2003-02-26
EP1600167A3 (en) 2009-09-30
EP1244456B1 (en) 2007-05-09
IL149530A (en) 2007-07-04
RO121085B1 (ro) 2006-12-29
HUP0204023A3 (en) 2005-03-29
BR0015974A (pt) 2002-07-23
CN100525761C (zh) 2009-08-12
CZ20021904A3 (cs) 2002-11-13
DE60034815T2 (de) 2008-01-31
SA01210655B1 (ar) 2006-10-29
CO5261590A1 (es) 2003-03-31
EP1244456A1 (en) 2002-10-02
JP4249415B2 (ja) 2009-04-02
EP1600167A2 (en) 2005-11-30
HK1052647A1 (en) 2003-09-26
EE200200274A (et) 2003-06-16
IL149530A0 (en) 2002-11-10
AU773418B2 (en) 2004-05-27
ES2287039T3 (es) 2007-12-16
SK7492002A3 (en) 2003-02-04
EP1600168A2 (en) 2005-11-30
EP1600168A3 (en) 2009-09-23
YU37602A (sh) 2005-07-19
NO20022585L (no) 2002-07-25
JP2008056697A (ja) 2008-03-13
PL357472A1 (en) 2004-07-26
RU2002117279A (ru) 2004-02-27
RU2261093C2 (ru) 2005-09-27
CN1402637A (zh) 2003-03-12
BG106708A (bg) 2003-02-28
EP1600169A3 (en) 2009-09-23
EP1600169A2 (en) 2005-11-30
JP2003515564A (ja) 2003-05-07
US6903130B1 (en) 2005-06-07
WO2001039779A1 (en) 2001-06-07
ATE361751T1 (de) 2007-06-15
HK1052647B (zh) 2010-05-20
MY127980A (en) 2007-01-31
AR026610A1 (es) 2003-02-19
CA2475026A1 (en) 2001-06-07
CA2392879A1 (en) 2001-06-07
TWI238062B (en) 2005-08-21
AU1524101A (en) 2001-06-12

Similar Documents

Publication Publication Date Title
HUP0204023A2 (hu) Pirrolidinacetamidszármazék alkalmazása önmagában vagy kombinációban központi idegrendszeri zavarok kezelésére és ezeket tartalmazó gyógyszerkészítmények
BG105005A (en) Pyrazoline derivatives, their preparation and application as medicaments
HUP0203325A2 (hu) Biciklusos aminosavak, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
GEP20053595B (en) Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment
HUP0302474A2 (hu) Terápiásan hatásos tropánszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
SE0104340D0 (sv) New compounds
MY129422A (en) Medicinal compounds
TR200002207T1 (tr) Slekoksib bileşikleri.
BG104727A (en) Pharmaceutical composition of topiramate
ES2165969T3 (es) Compuestos nitrogenados aromaticos condensados 5,5 aril-sustituidos como agentes antiinflamatorios.
HUP0003351A2 (hu) 2-Szubsztituált-4,5-diaril-imidazolok, eljárás e vegyületek előállítására, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0103542A2 (hu) Opioid-receptor aktivitással rendelkező 4,4-biaril-piperidin származékok és a vegyületeket tartalmazó gyógyászati készítmények
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
CA2241904A1 (en) Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
ATE282418T1 (de) Orale verabreichung wirksamer mengen von hyaluronsäure
ES2193875A1 (es) Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
RU2007104774A (ru) Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
HUP0302068A2 (hu) COX-2 inhibitorok alkalmazása immundeficienciával járó rendellenességek kezelésére vagy megelőzésére és ezeket tartalmazó gyógyszerkészítmények
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
PL370529A1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
HUP0402577A2 (hu) Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra
YU84503A (sh) Upotreba azitromicina za pripremanje leka za lečenje neinfektivnih inflamatornih oboljenja
NZ767378A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees